Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Patients With Fanconi Anemia
NCT03206086Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Nov 2018
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in Fanconi anemia (FA), sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Proportion of Drug Responders at 6 months and Number of Participants With Eltrombopag-Related Adverse Events During the First 6 Months. Started Nov 2018; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
Fanconi anemia (FA)
Beyond the preview
Go deeper on NCT03206086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206086.